LucidQuest’s Post

Gene&Cell Therapy >> It takes GUTS to be BOLD: A look at the new biotech tickers: As the public markets heat up in biotech, industry insiders expect a small drumbeat of IPOs later this spring, and that means a new set of stock tickers to track. Next up is BOLD, the proposed name of Boundless Bio’s Nasdaq stock. Using that name would mark a return for the ticker, which freed up after Astellas bought Audentes Therapeutics for $3 billion in 2019. Boundless is expected to make its Wall Street debut in the coming weeks after unveiling plans to go public earlier this month. Biotech tickers have traditionally stuck to letters that encompass their name, like RayzeBio’s RYZB. Others rely on their chosen modality, like Moderna’s MRNA. And some go the route of the technology they’re deploying — like Editas Medicine’s EDIT for gene editing, while four-letter names often beget four-letter symbols, like JAZZ. Joshua Pinto “You want to make it unique to the company so it’s really like a branding event,” Neumora CFO Joshua Pinto said in an interview. “Second, you want to make it easy to remember.” Neumora, a Phase III neuroscience biotech, went public in September as NMRA. In its early days, the ARCH Venture Partners startup went by the nickname of “Really Big Neuroscience Company.” “I won’t say what choice No. 2 or 3 was, but as you could imagine, we had some fun with some of the prior acronyms behind the company,” Pinto said. One recent entrant also took a playful approach. In its January IPO, Fractyl Health, a Massachusetts biotech working on cardiometabolic medicines, went with GUTS — a play on both gut health and bravery. “We’ve been talking about intestinal fortitude from the perspective of the tenacity and commitment and conviction required to be successful,” Fractyl CEO Harith Rajagopalan said in an interview, “but then also intestinal fortitude, as something that is impaired in people with obesity and metabolic disease.” Harith Rajagopalan On the day of its IPO, Fractyl gave its employees T-shirts with the phrase, “No guts, no glory.” The biotech plans to start testing its GLP-1 gene therapy in humans as a potential type 2 diabetes treatment in the first half of next year. “The greatest ticker symbol of all time was Genentech’s use of DNA back in the day,” Rajagopalan said. “You think, ‘Well, what are we trying to convey with this ticker symbol about who we are, about what we do, about the way in which we do it?’ GUTS was just too good to pass up on.” DNA is now the ticker for Ginkgo Bioworks, a synthetic biology company that has seen its valuation crater since going public in 2021. As more biotechs go public, they’ll have to be creative with their ticker symbols to stand out in what may be an increasingly crowded field — and many obvious choices are already in use. Take BioAge Labs, which just… #lucidquest #genetherapy #celltherapy

Did you miss the biotech rebound? According to Jefferies, public biotechs have raked in $10 billion this year, and the XBI is up over 50%! Gene therapy leaders like Precision Biosciences and Advernum Biotech are driving the momentum. https://loom.ly/tbdKi2Q #FOMO #biotech #investing Are you seeing this trend too? Let us know with a 👍

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> AbbVie’s next CEO; $100B club refresh; Top 100 VCs, 2023; More hope for CAR-T in autoimmune; and more: Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here. Is this the big turnaround year for biotech investment? If you missed John Carroll’s panel discussion on the topic, you can now watch the video on-demand here. AbbVie’s next CEO After months of speculation, AbbVie announced CEO Richard Gonzalez will hand the CEO post to president and COO Robert Michael on July 1. As the Chicago-area Big Pharma progresses through its transition from Humira with expectations of major revenue loss, Michael will be tasked with building a new empire, in part on two recently-inked acquisitions. $100B club refresh For the first time, Regeneron and Vertex have crossed the $100 billion market cap threshold — joining about 15 other drugmakers that count as the industry’s biggest and include other giants like Johnson & Johnson, Merck, and Novartis. Andrew Dunn takes a look at what the induction of these new heavyweights says about the industry. Top 100 VCs, 2023 2023 marks one of those years in life sciences when venture capital spent a lot of time looking for ways to preserve cash runways and finding bridges to human data. Endpoints’ John Carroll and DealForma chief Chris Dokomajilar break it all down with this year’s top 100 list of biotech investors, complete with analysis of trends regarding rounds, therapeutic areas and stages. More hope for CAR-T in autoimmune Just as new details from the first 15 autoimmune disease patients treated with CAR-T therapy added enthusiasm to the idea, Galapagos said it will pull out of the field, which it says is “very crowded.” As part of the decision, it will drop plans for a trial in systemic lupus erythematosus. Proteomics reinvigorated Once a scientific backwater, protein research has seen a surge of activity in recent months, attracting billion-dollar deals and high-profile publications. Jared Whitlock digs into how better instruments have let researchers tap the proteome to develop new tests and medicines, as well as the challenges in scaling the technology. R&D * Alnylam’s surprise change to the analysis plan for one of this year’s most anticipated clinical trial readouts set off a flurry of questions about the future of the company’s ATTR franchise and the outlook of its upcoming results. In an interview, CEO Yvonne Greenstreet told Lei Lei Wu the changes are a reflection that “we really are playing to win.” * NodThera is moving its NLRP3 inhibitors into the clinic after preclinical data showed it reversed obesity and… #lucidquest #genetherapy #celltherapy

What Have We Seen in the Biotech Industry in H2 so far? The biotech sector in 2024 continues to showcase resilience and advancement, surmounting challenges from previous years. Here's a snapshot of the latest developments: The SPDR S&P Biotech ETF (XBI) has surged by 22% since April, buoyed by decreasing inflation rates and the potential for interest rate cuts. Breakthroughs in weight-loss treatments have attracted significant investments, underscoring the industry's adaptability and ingenuity. Amidst rising interest rates, substantial funding rounds are reshaping the financial landscape. Mirador Therapeutics, for instance, secured $400 million in Series A funding, highlighting sustained investor interest in promising biotech ventures. Collaborations and mergers are reshaping the industry, with major pharmaceutical companies joining forces to enhance their pipelines and reduce R&D risks. Robust M&A activities are benefiting both large and small biotech firms, surpassing 2023 levels. As 2024 unfolds, the biotech industry is making significant strides in market recovery, funding initiatives, and technological breakthroughs. Its adeptness in navigating economic challenges while leading pioneering research solidifies its position as a sector to closely monitor in the upcoming months.

Exciting times in biotech as the sector hits a two-year high, driven by groundbreaking developments in psychiatric drug development and notable achievements by Viking Therapeutics, Inc. and Janux Therapeutics. This resurgence underscores the sector's innovative potential, moving beyond macroeconomic factors to truly transformative medicine. Strategic Independence and Genome Editing - Cytokinetics' decision to stay independent amidst M&A rumors, and Beam Therapeutics' strategic maneuvering in genome editing, highlight the nuanced strategies behind biotech successes. The Rise of TechBio - Recursion's innovative "TechBio" approach, blending AI with drug discovery, introduces a new paradigm, though aligning market expectations remains a challenge. Engage and Reflect - As biotech continues to evolve, let's discuss how these innovations and strategic decisions will shape healthcare's future. What impact do you foresee for patients and the industry at large? #BiotechInnovation #HealthcareFuture #TechBio

𝗧𝗵𝗲 𝗰𝗹𝗮𝘀𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗯𝗲𝘀𝘁 𝗶𝗻 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 - 𝗧𝗼𝗽 𝟭𝟱! 🔥 Biotech is a highly saturated to say the least with so many coming and going within such a short period of time. This makes it very difficult to have an in depth view of who is leading the discovery curve for new therapeutics with such bold claims presented weekly. However, luckily we have our friends over at Fierce Biotech who have done the ground work for us! Check out the link below on this super exciting read on who to keep an eye on! 𝗛𝗮𝘃𝗲 𝗮 𝗹𝗼𝗼𝗸 𝘆𝗼𝘂𝗿𝘀𝗲𝗹𝗳 𝗮𝗻𝗱 𝗹𝗲𝘁 𝗺𝗲 𝗸𝗻𝗼𝘄 𝘄𝗵𝗼 𝘆𝗼𝘂 𝘄𝗼𝘂𝗹𝗱 𝗵𝗮𝘃𝗲 𝗶𝗻𝗰𝗹𝘂𝗱𝗲𝗱 𝗮𝗻𝗱 𝘁𝗮𝗴 𝘁𝗵𝗲𝗺 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁 𝘀𝗲𝗰𝘁𝗶𝗼𝗻 𝗯𝗲𝗹𝗼𝘄 Companies included are: Abdera Therapeutics Ascidian Therapeutics BigHat Biosciences Cour Pharmaceuticals Development Co., Inc. Excision BioTherapeutics Fauna Bio Gilgamesh Pharmaceuticals iECURE, inc. ILiAD Biotechnologies, LLC Kimer Med NodThera OMass Therapeutics ProFound Therapeutics Recludix Pharma Tubulis GmbH #Biotech #Therapeutics #BiotechNews https://lnkd.in/eX3g_wgP

𝗧𝗵𝗲 𝗼𝗽𝘁𝗶𝗺𝗶𝘀𝗺 𝗮𝗻𝗱 𝗰𝗼𝗻𝗳𝗶𝗱𝗲𝗻𝗰𝗲 𝘀𝗲𝗲𝗺𝘀 𝘁𝗼 𝗯𝗲 𝗿𝗲𝘁𝘂𝗿𝗻𝗶𝗻𝗴 𝘁𝗼 𝗯𝗶𝗼𝘁𝗲𝗰𝗵! 6 IPOs and 2 Acquisitions announce whilst at JP Morgan conference this year! ICON did a survey of over 100 Biotechs and saw that 60% of these who did respond indicated that their R&D spending is to increase over the next 2 years. Good science is getting funded and there is capital available. This is shown by seeing over 50 companies since January this year secure more a minimum of $50M each. What are your thoughts on the market and what topics are you discussing more and more? Id love to hear in the comments below! ------------- 𝗙𝘂𝗿𝘁𝗵𝗲𝗿 𝘁𝗼 𝘁𝗵𝗶𝘀, 𝗶𝗳 𝘆𝗼𝘂 𝗮𝗿𝗲 𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘁𝗼 𝗵𝗶𝗿𝗲 𝗶𝗻 𝗰𝗼𝗺𝗽𝗹𝗲𝘅 𝗿𝗼𝗹𝗲𝘀 𝘁𝗵𝗮𝘁 𝗮𝗿𝗲 𝗱𝗲𝘁𝗿𝗶𝗺𝗲𝗻𝘁𝗮𝗹 𝘁𝗼 𝘆𝗼𝘂𝗿 𝘀𝘂𝗰𝗰𝗲𝘀𝘀, 𝗽𝗹𝗲𝗮𝘀𝗲 𝗿𝗲𝗮𝗰𝗵 𝗼𝘂𝘁 𝗮𝘀 𝗜 𝗮𝗺 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝘀𝗼𝗺𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗳𝗼𝗹𝗹𝗼𝘄𝗶𝗻𝗴 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 𝘁𝗵𝗮𝘁 𝗵𝗮𝘃𝗲 𝗮 𝗽𝗿𝗼𝘃𝗲𝗻 𝘁𝗿𝗮𝗰𝗸 𝗿𝗲𝗰𝗼𝗿𝗱 𝗶𝗻 𝘁𝗵𝗲𝗶𝗿 𝗳𝗶𝗲𝗹𝗱. 𝗖𝗠𝗖 & 𝗦𝘂𝗽𝗽𝗹𝘆 𝗖𝗵𝗮𝗶𝗻 - 𝗦𝗺𝗮𝗹𝗹 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀 𝗛𝗲𝗮𝗱 𝗼𝗳 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗔𝗳𝗳𝗮𝗶𝗿𝘀 - 𝗡𝗼𝘃𝗲𝗹 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗛𝗲𝗮𝗱 𝗼𝗳 𝗤𝗔 - 𝗖𝗚𝗧 𝗛𝗲𝗮𝗱 𝗼𝗳 𝗤𝗖 - 𝗦𝗺𝗮𝗹𝗹 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀 𝗦𝗲𝗻𝗶𝗼𝗿 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿 𝗼𝗳 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 - 𝗔𝗶 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 Watch the youtube clip for further insights below: https://lnkd.in/en7VXUBK #Biotech #CDMO #MasonHarding #CellTherapy #NovelDrugDiscovery

Bright Minds Biosciences just gave Wall Street the trip of a lifetime. Last week, the small psychedelic drug developer saw its stock skyrocket over 3,000% in a matter of days. In fact, the $DRUG surge was so potent it lifted the entire AdvisorShares Psychedelics ETF by 70%. How’s that for a contact high? Bright Minds must have just dropped some immaculate trial data, huh? Nope. The pump began when pharma giant Lundbeck announced it would acquire Longboard Pharmaceuticals for $2.6 billion. See, Bright Minds and Longboard are both cooking up 5-HT2C receptor drugs for epilepsy, so the deal put a spotlight on Bright Minds' potential. Never mind that they're a step behind in trials… When has a little thing like "evidence" ever stopped a good speculative stock frenzy? Bright Minds, for its part, initially issued a statement claiming no material changes to explain the madness. But they sure know how to ride a wave. Since then, they’ve announced a $35 million private placement and an AI partnership with Firefly Neuroscience. Just remember, what goes up must come down, and the landing isn't always soft. So try not to YOLO your life savings into the market, no matter what r/shroomstocks says.

With 2024 set to be a strong IPO year 🚀, the highly innovative life sciences industry is especially well-positioned to capitalize. 💡 Anticipating cuts in interest rates as a result of easing inflationary pressures 📉, the financial markets have seen indices such as the S&P 500, DAX, and CAC 40 reach record highs 📈. This buoyancy has led to a continuous increase in investor appetite for IPOs. During 2023 and Q1 2024, the largest 15 US and European IPOs successfully raised close to $30 billion. Flagship European life sciences IPOs like Galderma, Schott Pharma, and Renk fared especially well, underscoring the market’s interest in this dynamic sector. 🔬 We have identified six trends powering that dynamism: 🚀 🚀 Quest for Eternal Life Fuels Expanding Longevity Industry 💡 Smart Implants Elevate Post-Surgery Outcomes 🤖 AI & ML Revolutionize Clinical Trials 🕵️ Structured Data Improves Disease Surveillance 🌟 Radiopharmaceuticals Market Expected to Grow Significantly 🧬 Gene Therapy Transforms Treatment of Sickle Cell and Other Diseases These trends highlight the sector’s readiness for investment and mark life sciences IPOs as a particularly compelling opportunity in 2024. 📊 If you have any questions, please reach out to Anders Elgemyr, Caspar Graf Stauffenberg, or Oskar Wollert. 🤝 #ipo #lifesciences

https://conta.cc/4dg3E1y The past week was filled with headline grabbing news, especially those related to Asian biotech or Asian biotechies: 1. Summit/Akeso’ “Keytruda killer” lived up to the expectation and dominated the headlines of all major biotech news outlets, and CNBC, which we elaborated with a commentary. 2. Candid Therapeutics debuted in the red hot T-cell engager for autoimmunity space, backed by Asian innovations, capital, and talents. Our commentary reveals the strong Asian support behind Candid’s impressive launch. 3. Yesterday, a few very experienced Asian biotech executives shared their insights on the global landscape of investment, deal-making, and partnership, under the new reality shaped by inflation reduction act and biosecure act in the biotech epicenter Kendall Square. BioVerse 13 continued the success streak of our webinar series, and this one was particularly timely after the launch of Candid Therapeutics, whose Phase 1 BCMA-targeted T-cell engager was developed by David Gu’s company EpimAb Biotherapeutics. In addition, Proteologix CEO David Shen told the backstory behind his $850M acquisition by JNJ, while Kaveri Pohlman provided rich context of why I&I is so attractive. Watch the webinar replay here and read the summary here.